| scholarly article | Q13442814 |
| P2093 | author name string | L. Morris | |
| J. Overbaugh | |||
| P2860 | cites work | Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 |
| Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region | Q37410792 | ||
| Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens | Q37456354 | ||
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? | Q37519312 | ||
| Specificities of broadly neutralizing anti-HIV-1 sera | Q37667735 | ||
| HIV-1 superinfection and its implications for vaccine design | Q37807440 | ||
| Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates | Q38900264 | ||
| Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. | Q39457063 | ||
| Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site | Q39699375 | ||
| Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. | Q39879382 | ||
| Unlocking the secrets of CTL and NK cells | Q40422879 | ||
| Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers | Q40659603 | ||
| Features of HIV-1 that could influence maternal-child transmission | Q41449046 | ||
| Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1 | Q41816066 | ||
| Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers | Q43215260 | ||
| Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection | Q43466756 | ||
| Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates | Q44219287 | ||
| Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection | Q44277098 | ||
| The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques | Q44357802 | ||
| Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
| Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. | Q45753210 | ||
| Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection | Q45753336 | ||
| Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group | Q45756465 | ||
| Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors | Q45759636 | ||
| Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection | Q45760115 | ||
| Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors | Q45772545 | ||
| Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype | Q45785271 | ||
| Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants | Q45867857 | ||
| Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. | Q45987356 | ||
| FcgammaRIIa genotype predicts progression of HIV infection. | Q46017436 | ||
| Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. | Q46078929 | ||
| Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody | Q46352552 | ||
| Fc receptor but not complement binding is important in antibody protection against HIV. | Q46545827 | ||
| HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers | Q46690098 | ||
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate | Q46775963 | ||
| Prevention of HIV infection by passive immunization with HIV immunoglobulin | Q47571809 | ||
| Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission | Q47878972 | ||
| Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. | Q51942600 | ||
| Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression | Q56886558 | ||
| Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 | Q64378954 | ||
| HIV-specific cellular and humoral immune responses in primary HIV infection | Q71621033 | ||
| Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1 | Q72371328 | ||
| Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients | Q73851292 | ||
| Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection | Q77386243 | ||
| A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects | Q77399464 | ||
| Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS | Q78678676 | ||
| HIV vaccine research: the way forward | Q81697043 | ||
| Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men | Q83124960 | ||
| Genotypic and phenotypic characterization of HIV-1 patients with primary infection | Q22242245 | ||
| Antibody vs. HIV in a clash of evolutionary titans | Q24536059 | ||
| Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection | Q24538985 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Gender differences in HIV-1 diversity at time of infection | Q24706473 | ||
| Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120 | Q27643185 | ||
| Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41 | Q27666159 | ||
| Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection | Q28286243 | ||
| Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection | Q28304764 | ||
| Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial | Q28305565 | ||
| Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection | Q28766705 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Structure of a V3-containing HIV-1 gp120 core | Q29619014 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. | Q30367176 | ||
| Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. | Q30369026 | ||
| Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection | Q30392301 | ||
| Human immunodeficiency virus vaccine trials | Q30424366 | ||
| Molecular analysis of HIV-1 gp120 antibody response using isotype IgM and IgG phage display libraries from a long-term non-progressor HIV-1-infected individual | Q30784281 | ||
| Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways | Q33504599 | ||
| Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection | Q33504604 | ||
| Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals | Q33526340 | ||
| HIV-1 and influenza antibodies: seeing antigens in new ways | Q33552488 | ||
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response | Q33664910 | ||
| Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission | Q33749206 | ||
| Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels | Q33780649 | ||
| Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells | Q33844334 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques | Q33966586 | ||
| Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. | Q34009945 | ||
| Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity | Q34057782 | ||
| HIV‐1 Transmission Biology: Selection and Characteristics of Infecting Viruses | Q34158525 | ||
| B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection | Q34239109 | ||
| Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant | Q34301874 | ||
| Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population | Q34314341 | ||
| The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection | Q34317025 | ||
| Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa | Q34332009 | ||
| Specificity of the autologous neutralizing antibody response | Q34415389 | ||
| Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. | Q34428738 | ||
| Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes | Q34439417 | ||
| Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus | Q34468698 | ||
| Lymphocyte-mediated cytotoxicity. | Q34542250 | ||
| Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positio | Q34583767 | ||
| B cells in HIV infection and disease | Q34605780 | ||
| Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy | Q34647680 | ||
| Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses | Q34651668 | ||
| Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants | Q34717113 | ||
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection | Q34982698 | ||
| The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection | Q35076717 | ||
| Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Q35101333 | ||
| Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa | Q35140032 | ||
| epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals | Q35192660 | ||
| Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. | Q35603504 | ||
| Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection | Q35635163 | ||
| Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission | Q35744396 | ||
| Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. | Q35852888 | ||
| Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. | Q35853750 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection | Q35857268 | ||
| Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. | Q35857408 | ||
| Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections | Q35857480 | ||
| Antiviral antibodies are necessary for control of simian immunodeficiency virus replication | Q35857503 | ||
| The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate | Q35869892 | ||
| Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones | Q36009232 | ||
| Antibodies: can they protect against HIV infection? | Q36173023 | ||
| In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers | Q36424125 | ||
| HIV transmission | Q36526615 | ||
| Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 | Q36625449 | ||
| Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection | Q36647820 | ||
| Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys | Q36683893 | ||
| Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques | Q36702206 | ||
| Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. | Q36829102 | ||
| Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection | Q36845710 | ||
| Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies | Q36884458 | ||
| Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response | Q36949880 | ||
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. | Q36974754 | ||
| Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses | Q36994644 | ||
| Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies | Q37033269 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques | Q37033311 | ||
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 | ||
| GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. | Q37063527 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1 | Q37256644 | ||
| Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease | Q37273122 | ||
| Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors | Q37333772 | ||
| Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. | Q37347813 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | a007039 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Medicine | Q21042440 |
| P1476 | title | The Antibody Response against HIV-1 | |
| P478 | volume | 2 |
| Q26829865 | A Blueprint for HIV Vaccine Discovery |
| Q35566508 | A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens |
| Q30596957 | A comparison of elasticities of viral levels to specific immune response mechanisms in human immunodeficiency virus infection. |
| Q36300767 | A mouse model for HIV-1 entry |
| Q99584175 | An Automated Fluorescence-Based Method to Isolate Bone Marrow-Derived Plasma Cells from Rhesus Macaques Using SIVmac239 SOSIP.664 |
| Q35109028 | An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus |
| Q26991572 | Antibody responses to envelope glycoproteins in HIV-1 infection |
| Q52671487 | Are microRNAs Important Players in HIV-1 Infection? An Update. |
| Q36080800 | Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1 |
| Q36692987 | Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. |
| Q38025633 | Basic research in HIV vaccinology is hampered by reductionist thinking |
| Q40721916 | Bayesian hierarchical modeling for subject-level response classification in peptide microarray immunoassays |
| Q36131738 | Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein |
| Q33592852 | Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System |
| Q27678062 | Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans |
| Q46683819 | Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning |
| Q36920299 | CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans |
| Q45333913 | CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children |
| Q33957908 | Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco |
| Q37060319 | Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate |
| Q35913921 | Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1 |
| Q36079024 | Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising |
| Q41610618 | Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains |
| Q36694111 | Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop |
| Q27654848 | Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity |
| Q34368932 | Deep Panning: steps towards probing the IgOme |
| Q36057328 | Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet |
| Q36102994 | Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens |
| Q37069837 | Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. |
| Q42207794 | Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner |
| Q27644515 | Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies |
| Q36086229 | Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif |
| Q64923249 | Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious Diseases. |
| Q40448856 | Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies. |
| Q36222292 | Experimental Estimation of the Effects of All Amino-Acid Mutations to HIV's Envelope Protein on Viral Replication in Cell Culture |
| Q40794254 | Exploring the benefits of antibody immune response in HIV-1 infection using a discrete model. |
| Q38649549 | Factors influencing mothers' decision to enroll their HIV-negative children in a hypothetical HIV vaccine trial. |
| Q92015755 | FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV |
| Q47193141 | Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies. |
| Q34555891 | Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity |
| Q36269097 | HIV transmission biology: translation for HIV prevention |
| Q38210557 | HIV vaccines: a brief overview. |
| Q30248405 | HIV-1 and hijacking of the host immune system: the current scenario |
| Q27000480 | HIV-1 neutralizing antibodies: understanding nature's pathways |
| Q40940285 | HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution |
| Q37484124 | HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study |
| Q37236504 | HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice |
| Q38192126 | Human immunodeficiency virus antibodies and the vaccine problem. |
| Q30362489 | Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? |
| Q39447992 | Immunological tolerance as a barrier to protective HIV humoral immunity |
| Q59354606 | Impaired Development and Expansion of Germinal Center Follicular Th Cells in Simian Immunodeficiency Virus-Infected Neonatal Macaques |
| Q36515119 | In vivo platforms for analysis of HIV persistence and eradication |
| Q57167018 | Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India |
| Q42182937 | Insight into the modified Ibalizumab-human CD4 receptor interactions: using a computational binding free energy approach |
| Q36009232 | Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones |
| Q42638889 | Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity |
| Q64097514 | Modeling the Effects of Morphine-Altered Virus Specific Antibody Responses on HIV/SIV Dynamics |
| Q87163708 | Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol |
| Q36957775 | Mucosal immunology of HIV infection |
| Q37415418 | Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding |
| Q91582856 | Neutralization and beyond: Antibodies and HIV-1 acquisition |
| Q27684529 | Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor |
| Q36433894 | New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency |
| Q41933431 | Pathogenic Correlates of the Simian Immunodeficiency Virus (SIV)-Associated B Cell Dysfunction |
| Q34273397 | Phages and HIV-1: from display to interplay |
| Q49885201 | Potential Epigenetic Regulation in the Germinal Center Reaction of Lymphoid Tissues in HIV/SIV Infection. |
| Q64265266 | Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope |
| Q38776093 | Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression |
| Q35929985 | Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis |
| Q97533602 | SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus |
| Q41019767 | Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults |
| Q41876895 | Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques |
| Q38050485 | Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. |
| Q52718554 | Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire. |
| Q34312037 | Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus |
| Q35641234 | Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection |
| Q36766857 | Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation |
| Q35985519 | Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability |
| Q64060305 | The Antibodiome-Mapping the Humoral Immune Response to HIV |
| Q47600020 | The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir |
| Q35902684 | The HIV Epidemic: High-Income Countries. |
| Q35765737 | The HIV-1 epidemic: low- to middle-income countries |
| Q92561961 | The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes |
| Q35926734 | The challenges of modelling antibody repertoire dynamics in HIV infection |
| Q38019332 | The design and evaluation of HIV-1 vaccines |
| Q92600927 | The potential of plant systems to break the HIV-TB link |
| Q34017550 | The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. |
| Q35000080 | The role of cell-associated virus in mother-to-child HIV transmission |
| Q34399656 | The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties. |
| Q98177674 | Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women |
| Q34874985 | Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients |
| Q92538999 | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
| Q38764543 | Use of broadly neutralizing antibodies for HIV-1 prevention |
| Q40198060 | Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop |
Search more.